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Introduction 50 
The rates and routes of lethal systemic spread in breast cancer are poorly 51 
understood due to the lack of molecularly characterized cohorts with long-term, 52 
detailed follow-up. Long-term follow-up is especially essential for ER-positive (ER+) 53 
breast cancer, where tumors continue to recur up to two decades after initial 54 
diagnosis1–6 and there is a critical need to identify high-risk patients prior to lethal 55 
recurrence7–9. Here we present a statistical framework to model distinct disease 56 
stages (loco-regional recurrence (LR), distant recurrence (DR) and breast cancer-57 
related death) and competing risks of breast cancer mortality, while yielding 58 
individual risk of recurrence predictions. Application of this model to 3240 breast 59 
cancer patients, including 1980 with molecular data, delineates the spatio-temporal 60 
patterns of relapse across the immunohistochemical (IHC), intrinsic (PAM50)10,11, 61 
and integrative (IntClust)12,13 subtypes. We identify four late-recurring integrative 62 
subtypes, comprising a quarter (26%) of ER+, human epidermal growth factor 63 
receptor 2-negative (HER2-) tumors, each with characteristic genomic copy number 64 
driver alterations and high (median 42-55%) risk of recurrence up to 20 years post-65 
diagnosis. Additionally, we define a subgroup of triple-negative breast cancers 66 
(TNBC) that rarely recur after 5 years and a separate subgroup that remain at risk. 67 
The integrative subtypes improve prediction of late distant relapse beyond clinical 68 
covariates (nodal status, tumor size, grade and IHC subtype). These findings 69 
illuminate opportunities for improved patient stratification and biomarker-driven 70 
clinical trials. 71 
 72 
Main 73 
Breast cancer is a multistate disease with clinically relevant intermediate endpoints 74 
such as LR and DR14. Critically, a patient’s prognosis can differ dramatically 75 
depending on when and where a relapse occurs, time since surgery, and time since 76 
LR or DR15,16 These events are associated, and individual survival analyses of 77 
disease-free survival (DFS) or overall survival (OS) alone cannot fully capture 78 
patterns of recurrence associated with differential prognosis. Additionally, most 79 
survival analyses employ disease-specific death (DSD) as the primary endpoint and 80 
censor natural deaths. However, when competing risks of mortality occur, this 81 
approach induces bias17. This is particularly problematic for breast cancer, where 82 
ER+ patients experience higher mortality from non-malignant causes due to their 83 
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increased age at diagnosis relative to ER- patients. We evaluated the extent of such 84 
bias on breast cancer survival estimates by analysing 3240 patients diagnosed 85 
between 1977-2005 with median 14 years clinical follow-up (referred to as the Full 86 
Dataset FD; Extended Data Fig.1, Supplementary Table 1, Methods). We 87 
compared the naïve cumulative incidence for DSD (computed as 1 – the survival 88 
probability) stratified by ER status considering only cancer-related deaths (Extended 89 
Data Fig.2a) relative to the estimates with the proper cumulative incidence functions 90 
accounting for different causes of death (Extended Data Fig.2b). These 91 
comparisons indicate that the incidence of DSD is overestimated for ER+ tumors 92 
(0.46 vs 0.37 at 20 years) due to the increased age of diagnosis (median 63.9 vs 93 
53.0 years; p-value <1E-6) (Extended Data Fig.2c) relative to ER- tumors. 94 
Moreover, because the baseline survival functions for these subgroups are distinct, 95 
their differences cannot be adequately summarized with a single parameter in a Cox 96 
proportional hazards model. 97 
To overcome these limitations, we developed a non-homogenous (semi) 98 
Markov chain model that accounts for different disease states (LR, DR) and 99 
timescales (time since surgery, LR or DR), as well as competing risks of mortality 100 
and distinct baseline hazards across molecular subgroups, thereby enabling 101 
individual risk of relapse predictions (Fig.1a, Methods). The model also incorporates 102 
clinical variables known to influence breast cancer survival18,19, including age, tumor 103 
grade, tumor size and number of positive lymph nodes (all measured at diagnosis).  104 
We refer to this as the base clinical model onto which molecular subtype information 105 
can be incorporated. We fit this multistate model to the FD and recorded the hazards 106 
of moving through distinct states and the number of transitions between each pair of 107 
states (Supplementary Table 2, Methods). As expected, the majority of cancer 108 
related deaths (83% in ER+ and 87% in ER- tumors) occurred after distant 109 
metastasis. The remainder of cases likely reflect undetected recurrences or death 110 
due to other malignancies. Age at diagnosis was associated with the transition to 111 
death by other causes (p-value < 1E-6). Examination of the log hazard ratios and 112 
95% confidence intervals for all other variables indicated that their effect decreased 113 
with disease progression (Extended Data Fig.2d). That is, clinical variables related 114 
to the primary tumor were more prognostic for earlier transitions than for later 115 
transitions. However, several tumor characteristics informed the risk of progression 116 
from LR to DR and from DR to death. In ER+ disease, higher tumor grade, number 117 
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of positive lymph nodes and tumor size all increased the risk of progression to a later 118 
state. A longer time between surgery and LR or DR decreased the risk of transition 119 
to a later state and was more pronounced in ER- disease. We confirmed that our 120 
models were well calibrated, concordant with the established tool PREDICT18 and 121 
that they performed comparably in external datasets (Extended Data Fig.1, 122 
Extended Data Fig.3, Methods, Supplementary Information). 123 
A powerful feature of our multistate model is that hazard rates can be 124 
transformed into transition probabilities representing the probability of moving from 125 
one state into another after a given time. To evaluate the patterns of recurrence 126 
across the established breast cancer molecular subgroups, we turned to the 127 
METABRIC molecular dataset (MD) composed of 1980 patients (Extended Data 128 
Fig.1), which includes assignments to the IHC subtypes (ER+/HER2+, ER+/HER2-, 129 
ER-/HER2+, ER-/HER2-), PAM5011 expression subtypes and the genomic driver 130 
based IntClust subtypes12,13 (Supplementary Table 3). We computed the baseline 131 
transition probabilities from surgery, LR or DR at various time intervals (2, 5, 10, 15 132 
and 20 years) and the corresponding standard errors (SE) for average individuals in 133 
each subgroup (using the FD for comparisons by ER status and the MD for all 134 
others, Supplementary Table 4). After surgery, state transitions differed 135 
substantially across the various subtypes (Fig.1b). For example, the transition 136 
probabilities post surgery reveal different change points for ER+ versus ER- disease 137 
where ER- patients had a higher risk of DR and cancer death (D/C) in the first five 138 
years, after which their risk decreased considerably. In contrast, ER+ patients had a 139 
smaller, but longer risk period during the first ten years and this increased at a lower 140 
rate. Among ER- patients, the PAM50 Basal-like subgroup was nearly 141 
indistinguishable from the ER-/HER2- subgroup with the majority of cancer deaths in 142 
the first 5 years, similar to HER2+ patients (prior to the widespread use of 143 
trastuzumab). In contrast, the three predominantly ER- IntClust subgroups 144 
(IntClust4ER-, IntClust5 and IntClust10) exhibited substantial differences in their 145 
recurrence trajectories. As expected, IntClust5 (HER2+ enriched) generally had poor 146 
prognosis at 5 years (0.48, SE=0.04) with risk increasing to 0.65 (SE=0.04) at 20 147 
years. For IntClust10 (Basal-like enriched), the first 5 years from surgery largely 148 
defined patient outcomes: the probability of relapse at 5 years was 0.33 (SE=0.03) 149 
and after 20 years rose to only 0.37 (SE=0.04) for an average patient. This pattern 150 
was distinct from IntClust4ER- patients who exhibited a persistent and increasing 151 
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risk of relapse with a probability of 0.30 (0.05) at 5 years and 0.49 (0.05) after 20 152 
years.  153 
The distinction between IntClust4ER- and IntClust10 is further apparent when 154 
examining the average probabilities of relapse among all patients across the IntClust 155 
subtypes after surgery or after being disease-free for 5 and 10 years (Fig.2a). 156 
Indeed, through the course of the disease, the risk of relapse changed considerably 157 
across the integrative subtypes and to a lesser extent the IHC and PAM50 subtypes 158 
(Fig.2a, Extended Data Fig.4). Moreover, the probabilities of DR or cancer death 159 
amongst ER-/Her2- patients who were disease free at 5 years post diagnosis 160 
revealed low (IntClust10) and high (IntClust4ER-) risk of late relapse TNBC 161 
subgroups, whereas IHC (and PAM50) subtypes homogenized this risk (Extended 162 
Data Fig.5). 163 
Dramatic differences were also apparent amongst ER+ patients with 164 
IntClust3, IntClust7, IntClust8 and IntClust4ER+ exhibiting better prognosis while 165 
IntClust1, IntClust2, IntClust6 and IntClust9 corresponded to late-recurring poor 166 
prognosis patients (Fig.2a). These four subgroups had exceedingly high-risk of 167 
relapse with mean probabilities ranging from 0.42 to 0.56 up to 20 years post 168 
surgery. IntClust2 exhibited the worst prognosis with a probability of relapse (0.56, 169 
SE: 0.02) second only to IntClust5.  Collectively, these subgroups comprise 26% of 170 
ER+ cases (Fig.2bc) and thus define the minority of patients who may benefit from 171 
extended monitoring and treatment given the chronic nature of their disease5,6.  172 
Importantly, the four high-risk of relapse subgroups were enriched for 173 
characteristic genomic copy number alterations, which represent the likely drivers of 174 
each subgroup (Fig.2b). For example, IntClust2 tumors were defined by 175 
amplification and concomitant over-expression of multiple oncogenes on 176 
chromosome 11q13, including CCND1, FGF3, EMSY, PAK1 and RSF120–22. 177 
IntClust2 accounts for 4.5% of ER+ cases, 96% of which have RSF1 amplification, 178 
compared to 0-22% of other subgroups. IntClust6 (5.5% of ER+ tumors) are 179 
characterized by focal amplification of ZNF70323 and FGFR124 on chromosome 8p12 180 
(100% of IntClust6 cases vs. 2-21% of others). IntClust1 (8% of ER+ tumors) 181 
exhibited amplification of chromosome 17q23 spanning the mTOR effector, 182 
RPS6KB1 (S6K1)25, which was gained or amplified in 96% and 70% of cases, 183 
respectively (vs. amplification in 0-25% of others). IntClust9 accounted for another 184 
8% of ER+ cases and was characterized by amplification of the MYC oncogene at 185 
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8q24 with amplification in 89% of IntClust9 tumors (vs 3-42% of other groups). Thus 186 
the late-recurring ER+ subgroups are defined by genomic drivers, several of which 187 
are viable therapeutic targets 25–27. 188 
Similar differences in the probability of late distant relapse were seen in the 189 
subset of patients whose tumors were ER+/HER2- (Fig.3ab, Extended Data Fig.4a-190 
f), a group in which late relapse and strategies to target this, such as extended 191 
endocrine therapy, represent critical clinical challenges. In particular, the probabilities 192 
of DR or cancer death amongst patients who were disease free 5 years post 193 
diagnosis reveals significant risk for IntClust 1,2,6,9 (relative to IntClust3) that varied 194 
over time. Moreover, the risk was not fully captured by a model that included IHC 195 
subtype with clinical variables (age, tumor size, grade, number of positive lymph 196 
nodes, time since surgery) that have been shown to dictate distant relapse outcomes 197 
even after a long disease-free interval5 (Fig.3a). We therefore assessed whether the 198 
integrative subtypes provided information about a patient’s risk of late distant relapse 199 
above and beyond what could be inferred optimally from standard clinical 200 
information. We found that the model including clinical variables combined with IHC 201 
subtype provided substantial information about the probability of distant relapse in 202 
ER+/HER2- patients who were relapse-free at 5 years: C-index of 0.63 (CI 0.58-203 
0.68) at 10 years, 0.62 (CI 0.58-0.67) at 15 years, and 0.61 (CI 0.57-0.66) at 20 204 
years (Fig.3c). However, including the IntClust subtypes significantly improved its 205 
predictive value: C-index of 0.70 (CI 0.64-0.75; improvement over the clinical model 206 
P = 0.00011) at 10 years, 0.67 (CI 0.63-0.72, P = 0.0016) at 15 years, and 0.66 (CI 207 
0.62-0.71, P = 0.0017) at 20 years. These trends were recapitulated in an external 208 
validation cohort despite the smaller sample size and shorter follow-up times 209 
(prohibiting analyses at 20 years). Thus, information about the dynamics of late 210 
relapse provided by integrative subtype could not be inferred from standard clinical 211 
variables, including IHC subtype.  212 
We subsequently turned to the subset of patients who experienced a LR. LR 213 
is commonly treated with curative intent and is thought to be a high-risk event 214 
associated with increased rates (45 to 80%) of DR28. The transition probabilities after 215 
LR varied substantially according to pathological features of the primary tumor at 216 
diagnosis and molecular subtype, highlighting opportunities for intervention 217 
(Extended Data Fig.6, Extended Data Fig.7, Supplementary Tables 2-3). In 218 
contrast, following the initial DR all subgroups exhibited a high probability of cancer 219 
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death, although the median times differed (Extended Data Fig.8, Supplementary 220 
Tables 2-3).  221 
 Unique to our cohort is a subset of 618 patients (out of 1079 from the FD who 222 
relapsed) with a complete description of all recurrences (recurrent event dataset, 223 
RD), thereby enabling the detailed analysis of the rates and routes of distant 224 
metastasis and their lethality. These data revealed the varied time course over which 225 
metastases occurred and indicated that no sites of metastasis are exclusive to ER+ 226 
or ER- disease (Extended Data Fig.9a). Moreover, multiple distant metastases were 227 
common, even among favorable prognosis subgroups (Extended Data Fig.9b). We 228 
next examined the cumulative incidence and number of metastases at different 229 
organ sites stratified by ER status (Fig.4a). ER- cases harbored significantly more 230 
visceral disease (e.g. brain/meningeal: 27% vs. 11%, pulmonary: 50% vs. 41%) 231 
relative to ER+ cases. As previously reported29,30, bone metastases were more 232 
common in ER+ versus ER- cases (71% vs. 43%), but the cumulative incidence was 233 
similar. Thus, the higher proportions observed in ER+ disease appear not to reflect 234 
site-specific tropism: rather, bone metastases take a long time to develop, and ER- 235 
patients tend to die of other metastases first. ER+ tumors also more commonly 236 
present with the first metastasis in the bone (76% vs 61%). Similar comparisons 237 
stratified by IHC, PAM50, and IntClust subtypes revealed additional variability 238 
(Extended Data Fig.10). Striking differences in the rates of distant metastasis were 239 
also evident: ER- disease was characterised by a rapid series of relapses early after 240 
diagnosis, while most ER+ patients suffered just one early relapse (commonly bone) 241 
and if a second relapse occurred, the probability of additional relapses increased 242 
(Fig.4b, Methods). Thus after distant recurrence, subtype continues to dictate the 243 
rate of subsequent metastases, underscoring the importance of tumor biology. Both 244 
the number and site of relapses influenced the risk of death after recurrence with 245 
brain metastasis being most predictive. Risk estimates (Fig.4c) were comparable 246 
between ER+ and ER- tumors, suggesting that the impact of the site of metastasis 247 
on progression to death is similar.  248 
In summary, by leveraging a cohort of 3240 patients, including 1980 from 249 
METABRIC with detailed molecular characterization, LR and DR information, we 250 
have delineated the spatio-temporal dynamics of breast cancer relapse at 251 
unprecedented resolution. Our analyses are based on a powerful multi-state 252 
statistical model that yields individual risk of relapse estimates based on tumor 253 
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features, clinical, pathological and molecular covariates, as well as disease 254 
chronology, and is available via a web application (see URL below). Unlike existing 255 
models used to calculate the benefits of adjuvant therapy at diagnosis such as 256 
PREDICT18, this research tool can be used to assess how a patient’s risk of 257 
recurrence changes throughout follow-up. Learning whether specific treatments 258 
change the outcomes of different integrative subtypes is important and will require 259 
analysis of randomized clinical trial cohorts. 260 
By classifying breast tumors into the 11 integrative subtypes, important 261 
differences in recurrence rates that were obscured in the IHC and PAM50 subtypes 262 
became apparent. Amongst TNBC patients, IntClust10 largely remains relapse-free 263 
after 5 years, whereas IntClust4ER- patients continue to be at significant risk of 264 
recurrence. Amongst ER+/HER2-patients, IntClust 1, 2, 6, and 9 have markedly 265 
increased risk of DR up to 20 years post-diagnosis and together account for one 266 
quarter of all ER+ tumors and the vast majority of late recurrences. Moreover, the 267 
integrative subtypes significantly improved the prediction of distant recurrence after 5 268 
years in ER+/HER2- patients. Our findings thus address one of the contemporary 269 
challenges in breast oncology, namely identification of the subset of ER+ patients 270 
with high-risk of recurrence and tumor biomarkers that are more predictive of 271 
recurrence than standard clinical covariates7,8. Integrative subtyping may help 272 
determine whether women who are relapse-free 5 years after diagnosis might benefit 273 
from extended endocrine therapy or other interventions to improve late outcomes. 274 
Critically, the four late-recurring ER+ subgroups are enriched for genomic copy 275 
number driver alterations that can be therapeutically targeted24–27, thus paving the 276 
way for new treatment strategies for these high-risk patient populations. 277 
 278 
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Figure legends 
 
Figure 1. A multistate model of breast cancer relapse enables individual risk of 
relapse predictions throughout disease progression. a. Graphical representation 
of the model. Nodes represent possible states and arcs possible transitions between 
states, where parameters that have an effect on the hazard are indicated. b. 
Subtype-specific risk of relapse at diagnosis. Transition probabilities from surgery to 
other states (DF=Disease-free, LR=Loco-regional relapse, DR=Distant relapse, 
D/C=Cancer specific death, D/O=Death by other causes) are shown for individual 
average patients across the breast cancer subtypes. Subtypes were defined based 
on ER status using the FD and for IHC, PAM50 and integrative (IntClust) subtypes 
using the MD. 95% confidence bands (shaded areas) were computed using the 
bootstrap (see Methods). 
 
Figure 2. The integrative breast cancer subtypes exhibit distinct patterns of 
relapse.  a. Mean probabilities of having a relapse after surgery and after being 5 
and 10 years disease-free for the patients in each of the 11 integrative (IntClust/IC) 
subtypes, ordered by increasing risk of relapse. IC3, IC7, IC8 and IC4ER+ represent 
lower risk ER+ subtypes; IC10 and IC4ER- TNBC subtypes with variable relapse 
patterns; IC1, IC6, IC9 and IC2 late relapsing ER+ subtypes; and IC5 HER2+ tumors 
prior to trastuzumab. Error bars represent 95% confidence intervals. The lower 
colored bar shows the prevalence of each integrative subtype in the breast cancer 
population. b. Frequencies of copy number amplifications in specific IntClust 
subtypes (IC1, IC6, IC9 and IC2). Putative driver genes indicated by an asterisk. c. 
Proportion of ER+ tumors that belong to the four late-relapsing IntClust subtypes. 
This analysis was done with the MD. 
 
 
Figure 3. The integrative subtypes improve prediction of late distant 402 
recurrence in ER+/HER2- breast cancer beyond clinical covariates. a. 403 
Probabilities of distant relapse (DR) or disease-specific death (DSD) amongst 404 
ER+/HER2- patients who were disease free at 5 years post diagnosis reveals 405 
significant risk for IntClust (IC) 1,2,6,9 relative to IC3, which varies over time and is 406 
not captured by the standard clinical model. Dots represent average probabilities and 407 
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error bars 95% confidence intervals. b. Average probabilities of DR or DSD for 408 
ER+/HER2- patients in the four late-relapsing subgroups relative to IC3 for patients 409 
who were relapse free five years post diagnosis. c. Evaluation of the utility of the IHC 410 
model relative to the IntClust model for predicting late DR in ER+/HER2- patients 411 
who were relapse-free at 5 years. C-indices are shown for both models at different 412 
time intervals in the METABRIC cohort (n=1337, ER+/HER2- n=1013) and the 413 
external validation cohort (n=1080, ER+/HER2- n=739). Error bars represent 95% 414 
confidence intervals. This analysis was done with the MD.  415 
 
 416 
Figure 4. Organ-specific patterns and timing of distant relapse in ER+ and ER- 
patients. a. Percentages of patients and cumulative incidence (1-Kaplan-Meier 
estimates) for each site of metastasis in ER+ and ER- cases. Upright triangles 
indicate significant positive differences and inverted triangles indicate significant 
negative differences in that group with respect to the overall mean (see Methods). b. 
Relapse-free survival curves for sequential recurrences in ER- (n=186) and ER+ 
(n=419) patients computed using a conditional PWP model. Each curve shows the 
probability of not having any other relapse for individuals that had a previous relapse. 
The top bar shows the median time until the n-th relapse. c. Log Hazard ratios of 
disease-specific death (DSD) with 95% confidence intervals of the time-dependent 
Cox model for distant relapse (DR) in ER- (n=179) and ER+ (n=410) patients. This 
analysis was done with the RD. 
Methods 
 
Clinical cohort 
We employed data from 3240 patients (with a median follow-up of 9.77 years overall, 417 
and 14 years amongst patients who remain alive) derived from five tumor banks in 418 
the UK and Canada diagnosed between 1977-2005. Primary breast tumors and 419 
linked pseudo-anonymized clinical data were obtained with ethical approval from the 420 
relevant institutional review boards. The METABRIC study protocol was approved by 421 
the ethics committees at the University of Cambridge and British Columbia Cancer 422 
Research Centre. Manual curation and basic quality control was performed on the 423 
data. Observations that had relapse times equal to zero or relapse times equal to the 424 
last observed time were shifted 0.1 days. Local relapses that occurred after distant 425 
relapses were omitted. In total, 11 cases with stage 4 were also removed from all 426 
analyses. Benign and phylloid tumors were also discarded. Last follow-up time or 427 
time of death was the final endpoint for all patients. Special care was taken to 428 
remove second primary tumors from the dataset. Clinical parameters, such as tumor 429 
grade, were not centrally reviewed, which can lead to variability in the estimation of 430 
their effects. Samples were allocated to three datasets depending on the information 431 
available. The Full Dataset (FD) Clinical and pathological variables are available for 432 
this cohort (15394 transitions from 3147 patients). For a subset of 1980 patients we 433 
previously described an integrated genomic analysis based on gene expression and 434 
copy number data12 and refer to this as the molecular dataset or METABRIC MD 435 
(9512 transitions from 1962 patients). For this cohort, tumors were stratified based 436 
on the IHC subtypes (ER+/HER2+, ER+/HER2-, ER-/HER2+, ER-/HER2-), the 437 
intrinsic subtypes (PAM50)10,11 and the integrative (IntClust) subtypes12,13. Finally, for 438 
a subset of patients who experienced distant metastasis (618 out of the 1079 who 439 
relapsed from the FD), the date of each recurrence is available, enabling analysis of 440 
their spatio-temporal dynamics. We refer to this as the recurrent events dataset RD. 441 
The three datasets are summarized in Extended Data Fig.1a with clinical details 442 
and basic parameters describing the intermediate endpoints of LR and DR across 443 
distinct subgroups in Supplementary Table 1. We also established an independent 444 
metacohort composed of 1380 breast cancer patients from eight cohorts enabling 445 
external validation of our findings, despite their shorter median follow-up (8 years) 446 
(Extended Data Fig.1b). We sought to use the maximum information available to fit 447 
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the models, keeping all the transitions with complete observations needed to 448 
estimate the hazard of that specific transition. Therefore, the total number of cases 449 
used in each model differs due to different missing values in clinical variables, 450 
molecular classification, etc that can affect different transitions. 451 
 452 
Model description 453 
The general model we fitted to our datasets is a multistate model that reflects the 454 
different risks of loco-regional relapse, distant relapse or disease-specific death 455 
conditioned on the current status of the patient. Although multistate survival models 456 
for breast cancer were proposed more than 60 years ago31, there are few such 457 
analyses in the literature14,32,33. Specifically, we employed a non-homogenous semi-458 
Markov Chain with two absorbent states (Death/Cancer and Death/Other) as shown 459 
schematically in Fig.1. The model was stratified by molecular subtype and used a 460 
clock-reset time scale, in which the clock stops (clock-reset) when the patient enters 461 
a new state.  Although there were a small number of transitions from distant to local 462 
relapse (15 ER+ cases and 7 ER-), we omitted the local relapse in these instances 463 
as we considered it redundant and only allowed transitions from local to distant 464 
relapse in our model. We also included the possibility of cancer death without a 465 
recurrence to account for cases where metastasis was not detected. R packages 466 
survival34 and mstate35 were used to fit the data. 467 
 Several covariates were included in the model: age at state entry (diagnosis 468 
or relapse), tumor grade, tumor size and the number of positive lymph nodes, all of 469 
them as continuous variables (although in the case of lymph nodes, all values larger 470 
than 10 lymph nodes were coded as 10, to avoid excessive influence in the slope 471 
from extreme cases). The time from diagnosis was also included as continuous. 472 
Note that these formulations are a simplification from the modelling in our previous 473 
work12, where age, size and lymph nodes were modelled non-linearly through 474 
splines. We have simplified these effects to reduce the number of parameters in the 475 
model, but also, in the case of age, because its non-linearity is only relevant when 476 
overall survival is the endpoint. 477 
 For dataset FD, a Cox model was fitted stratified on ER status. The effect of 478 
age on death/other causes was modelled with a different coefficient for each 479 
transition into non-malignant death (in each ER status), to account for differences in 480 
the age at relapse or diagnosis. Grade, Size and Lymph Nodes were allowed to have 481 
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different coefficients from the starting state to states of recurrence/cancer death for 482 
each ER status. Time since diagnosis had different coefficients from the starting 483 
state of relapse to states of recurrence/ cancer death for each ER status and time 484 
since LR had different coefficients from distant relapse state to cancer related death 485 
for each ER status. The time since LR was not predictive of the time to DR and 486 
therefore was not included in further analyses. 487 
 For dataset MD, and because of the large number of molecular subtypes, we 488 
reduced the number of parameters constraining their values to be the same for the 489 
different molecular subtypes. Based on different fits and the results of likelihood ratio 490 
tests we observed some effects to be markedly different between transitions: age 491 
had a coefficient for transitions from surgery or loco-regional relapse into death/other 492 
causes for all molecular subtypes and another for transitions from distant relapse 493 
into death/other causes. Grade and lymph nodes had a value for transitions from 494 
diagnosis and another for transitions from relapse to states of recurrence/death, 495 
identical for each molecular subtype. Size had a value for transitions from diagnosis 496 
and another for transitions from loco-regional relapse to states of recurrence/death, 497 
identical for each molecular subtype. Time since diagnosis had the same coefficient 498 
from the starting state of relapse to states of recurrence/death, identical for all 499 
molecular subtype. This model was fit three times, one for each molecular 500 
classification, based on ER/HER2 status (FourGroupsM), PAM50 (Pam50M) and the 501 
Integrative Clusters (ICM); each of them stratified by the respective molecular 502 
subgroups. We used a robust variance estimate in all models (option cluster(id) in 503 
coxph() function) and performed likelihood ratio tests in order to reduce the number 504 
of parameters in each model. Since the number of samples in the MD is smaller than 505 
the FD, we retained only the most important covariates and assumed the same 506 
effect in each subgroup.  507 
 508 
Transition probabilities for each molecular subtype 509 
Using the model fit, we obtained the hazards for each transition for a given 510 
individual. We used these hazards to compute the corresponding transition 511 
probabilities as follows. We employ a clock-reset model and define all probabilities 512 
starting at the time of entry to the last state. All times s, t are also defined starting 513 
from the time of entry. Let the set of states be {S=disease-free/after surgery, L=loco-514 
regional relapse D=distant relapse, C=cancer death, O=other cause of death}. We 515 
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condition on the vector of clinical covariates x, which includes the time from surgery 516 
(in the case of relapse this variable has an effect on the hazards). 517 
 518 
Transitions from distant relapse: 519 
Following14,36, we define the conditional probability of having no further event 520 
between times t and s for a patient with distant relapse at time t as  521 
  522 
Sୈ(s, t|x) = exp ቊ− න ቀλୈ,େ(u|x) + λୈ,୓(u|x)ቁ
ୱ
୲
 duቋ 
where λi,j (t|x) is the hazard of moving from state i to state j at time t with the vector of 523 
covariates x (including the time from surgery or age, that must be updated after a 524 
relapse) . 525 
 526 
Then, the prediction probabilities for each path are: 527 
 528 
πୈେ (u, t|x) = න λୈ,େ(s|x)
୳
୲
Sୈ(s, t)ds 
 529 
πୈ୓(u, t|x) = න λୈ,୓(s|x)
୳
୲
Sୈ(s, t)ds 
 530 
πୈ(u, t|x) = 1 − (πୈେ (u, t|x) + πୈ୓(u, t|x)) 
 531 
 532 
Transitions from loco-regional relapse: 533 
Similarly, we obtain: 534 
 535 
S୐(s, t|x) = exp ቊ− න ቀλ୐,ୈ(u|x) + λ୐,େ(u|x) + λ୐,୓(u|x)ቁ
ୱ
୲
 duቋ 
 536 
π୐ୈ,େ(u, t|x) = න λ୐,ୈ(s|x)
୳
୲
πୈେ (u − s, 0|x)S୐(s, t|x)ds 
 537 
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π୐ୈ,୓(u, t|x) = න λ୐,ୈ(s|x)
୳
୲
πୈ୓(u − s, 0|x)S୐(s, t|x)ds 
 538 
π୐ୈ(u, t|x) = න λ୐,ୈ(s|x)
୳
୲
πୈ (u − s, 0|x)S୐(s, t|x)ds 
 539 
π୐େ(u, t|x) = න λ୐,େ(s|x)
୳
୲
S୐(s, t|x)ds 
 540 
π୐୓(u, t|x) = න λ୐,୓(s|x)
୳
୲
S୐(s, t|x)ds 
 541 
π୐(u, t|x) = 1 − (π୐ୈ,େ(u, t|x) + π୐ୈ,୓(u, t|x) + π୐ୈ(u, t|x) + π୐େ(u, t|x) + π୐୓(u, t|x)) 
 542 
 543 
Transitions after surgery: 544 
 545 
 546 
Sୗ(s, t|x) = exp ቈ− න ቀλୗ,୐(u|x) +  λୗ,ୈ(u|x) + λୗ,େ(u|x) + λୗ,୓(u|x)ቁ du
ୱ
୲
቉ 
 547 
πୗ୐,ୈ,େ(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐ୈ,େ(u − s, 0)Sୗ(s, t|x)ds 
 548 
πୗ୐,ୈ,୓(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐ୈ,୓(u − s, 0)Sୗ(s, t|x)ds 
 549 
πୗ୐,େ(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐େ(u − s, 0)Sୗ(s, t|x)ds 
 550 
πୗ୐,୓(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐୓(u − s, 0)Sୗ(s, t|x)ds 
 551 
πୗ୐,ୈ(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐ୈ(u − s, 0)Sୗ(s, t|x)ds 
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 552 
πୗୈ,େ(u, t|x) = න λୗ,ୈ
୳
୲
(s|x)πୈେ (u − s, 0)Sୗ(s, t|x)ds 
 553 
πୗୈ,୓(u, t|x) = න λୗ,ୈ
୳
୲
(s|x)πୈ୓(u − s, 0)Sୗ(s, t|x)ds 
 554 
πୗ୐(u, t|x) = න λୗ,୐
୳
୲
(s|x)π୐ (u − s, 0)Sୗ(s, t|x)ds 
 555 
πୗୈ(u, t|x) = න λୗ,ୈ
୳
୲
(s|x)πୈ (u − s, 0)Sୗ(s, t|x)ds 
 556 
πୗେ(u, t|x) = න λୗ,େ
୳
୲
(s|x)Sୗ(s, t|x)ds 
 557 
πୗ୓(u, t|x) = න λୗ,୓
୳
୲
(s|x)Sୗ(s, t|x)ds 
 558 
πୗ (u, t|x) can be computed as 1 minus the sum of the others. 559 
 560 
Prediction probabilities for being in a particular state at a certain time can also be 561 
computed summing the appropriate paths. Note that the main difficulty in computing 562 
these probabilities is updating the corresponding hazards every time a transition 563 
occurs, as they may depend on variables that change over time or after a transition 564 
to a different state.  In our implementation we tried to follow the style in the mstate 565 
package35. 566 
 567 
Standard Errors for the transition probabilities in our model 568 
If our model was Markovian (as the clock-forward model), the transition probabilities 569 
could be easily computed through the product-integral representation37 and it would  570 
also be straightforward to obtain estimates of their standard errors. However, for our 571 
clock-reset model the estimation of standard errors is complicated, so we used a 572 
semi-parametric bootstrap approach to obtain such estimates38. Briefly, for every 573 
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bootstrap replicate (B=100), we sampled trajectories for each observation in our 574 
original dataset based on our fitted model. These trajectories were fitted to the 575 
original model and bootstrap hazards for the original average individuals were 576 
computed. Then, the formulas described earlier were used to obtain bootstrap 577 
transition probabilities. Because these bootstrap estimates are not likely to converge 578 
to the theoretical estimates in transitions with a small number of observed instances, 579 
we computed the standard deviation of the bootstrap estimates as an indication of 580 
the variability of these predictions for a given patient. 581 
 582 
Transition probabilities for specific events 583 
The transition probabilities obtained for each patient can be aggregated to obtain 584 
probabilities of visiting specific states (LR, DR) or specific endpoints. We used these 585 
probabilities in two ways: as an example of individual predictions for an average 586 
patient for each molecular subtype (based on typical or average values of each 587 
covariate), as in Supplementary Table 4B, Fig.1b, Extended Data Fig.6 and 588 
Extended Data Fig.8 together with a confidence interval computed using the 589 
obtained probabilities +/- 1.96 times the standard deviation of the bootstrap 590 
estimates described above, that represent variability around individual predictions. 591 
We also computed probabilities for all patients to show their distribution in each 592 
molecular subtype, as in Supplementary Table 4A and Fig.2a, Fig.3a, Extended 593 
Data Fig.4 and Extended Data Fig.5. Confidence intervals computed using the 594 
mean of the probabilities +/- 1.96 times the standard error of the mean represent 595 
variability around the mean in each subtype. 596 
 597 
Sites of relapse 598 
For the RD datasets, each patient can have several relapses. Instead of adding the 599 
site to our multistate models, we selected only patients who had distant relapse. 600 
First, in Fig.4a and Extended Data Fig.10, we tested if the proportions of relapses in 601 
each organ differed by molecular subtype. We fitted a logistic regression model with 602 
relapse as a binary variable and the sites of metastases as dependent variables. We 603 
computed simultaneous tests using the R package multcomp39 using the Dunnet 604 
method40. Only those proportions with a p-value smaller than 0.05 were considered 605 
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significant. In the same figures, cumulative incidence distributions for each organ 606 
were computed independently, that is, no competing risk model was fitted.   607 
We modelled recurrent distant metastases (Fig.4b) using the Prentice, Williams 608 
and Peterson41 (PWP) conditional model. This model allows for different baseline 609 
hazards for each consecutive recurrence while keeping at risk for recurrence i only 610 
those individuals that have experimented the recurrence i-1.   611 
Finally, in Fig.4c we fitted a Cox model with time dependent variables to 612 
estimate the hazard of having metastasis in each organ. We also included in this 613 
model the clinical variables from the primary tumor (tumor grade, tumor size and 614 
number of positive lymph nodes). 615 
 616 
Goodness of fit testing 617 
Goodness of fit testing was performed for all models. Proportional hazards 618 
assumption was tested using the Schoenfeld Residuals vs. time using the survival 619 
function cox.zph()34. None of the models showed covariates that violated the 620 
assumption, except the model for sites of metastasis (ER+), where the number of 621 
metastases and “other metastasis” were significant and the model for sites of 622 
metastasis (ER-) where grade and the number of metastases were significant. Visual 623 
inspection of the plots showed that the trend was roughly flat and thus the violation 624 
was not critical. In the model that includes ER, as previously shown ER violates the 625 
proportional hazard assumption. However, this model was only used to test 626 
differences in the hazard ratios of the other covariates according to ER. 627 
 628 
Model Validation and Calibration 629 
We validated each of the models using several approaches, as outlined below. 630 
 631 
Internal validation: 632 
We validated the global predictions of the model on all transitions using the bootstrap 633 
approach described in detail in42 using the rms R package. We used the following 634 
measures of predictive ability: 635 
• Somers' Dxy rank correlation (Dxy). This is 2(c-0.5), where c is the c-index 636 
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• Nagelkerke’s R2, which is the square root of the proportion of log likelihood 637 
explained by the model from the log likelihood that could be explained by a 638 
“perfect” model, with a penalty for model complexity 639 
• Slope shrinkage (slope), a measure of how much the estimates are affected 640 
by extreme observations 641 
• Discrimination index D, derived from the log-likelihood at the shrunken linear 642 
predictor 643 
• Unreliability index U, a measure of the difference between the model 644 
maximum log likelihood is from a model with frozen coefficients 645 
• Overall quality index Q, a normalized and penalized for unreliability log 646 
likelihood 647 
• g-index (g) on the log relative hazard (linear predictor) scale (Gini’s mean 648 
difference) 649 
 650 
Each measure was computed on the training set and on 200 bootstrap test sets, 651 
estimating the optimism and the corrected indexes for predictions at 5, 10 and 15 652 
years (see Extended Data Fig.3a). 653 
 654 
Internal calibration: 655 
We also employed the following procedure for model calibration as described in42: 656 
• Interpolation of the hazard function using splines (hare method) among all the 657 
cases as a general function of the predictor variables and time 658 
• Computation of the predicted values for a given time point (5, 10 or 15 years) 659 
• Computation of the differences between observed and predicted 660 
• Using 200 bootstrap datasets, computation of the optimism in those 661 
differences 662 
Extended Data Fig.3b shows a boxplot of the mean absolute error of all predictions. 663 
 664 
External calibration: 665 
As an external comparison of the predicted probabilities of our models, we used 666 
predict v2.118 , a tool that has been validated extensively. PREDICT uses a model 667 
with several variables (including the effect of treatment) and produces estimates of 668 
the probability of cancer-specific death (C/D) and non-malignant death (O/D), as well 669 
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as estimates of the effect of treatment. We compared the probabilities for these 670 
events with PREDICT using Pearson correlation (see Extended Data Fig.3cd). 671 
 672 
External validation: 673 
We used two sets of external samples to validate the predictions of our models: 674 
1) A set of METABRIC samples that were not used in the original study including 675 
121 patients with copy number data and 57 patients with expression data. We 676 
already had survival data from these patients (in fact they are part of the full 677 
dataset FD, but because they have not been used to fit the IntClust Model, they 678 
could be employed to test the validity of the c-index on an external dataset). We 679 
classified these tumours into IntClust groups using the iC1013 package. 680 
 681 
2) An external dataset of 1380 patients from 8 different cohorts and different 682 
survival information. We validated predictions of disease-specific survival (DSS), 683 
overall survival (OS), relapse-free survival (RFS) and distant-relapse free survival 684 
(DRFS). We compiled a metacohort by merging early breast cancer cohorts 685 
where expression data (Affymetrix array), outcome and covariates are available, 686 
including GSE19615 (DFHCC43),  GSE42568 (Dublin44), GSE9195 (Guyt245), 687 
GSE45255 (IRB/JNR/NUH46), GSE11121 (Maintz47), GSE6532 (TAM45), 688 
GSE7390 (Transbig48) and GSE3494 (Upp49). Original data (raw CEL files) were 689 
downloaded and pre-processed using the rma function from the affy50 package. 690 
The intensities were then quantile normalized and corrected for batch effects with 691 
the COMBAT function from the sva51 package. PAM50 was called using the 692 
genefu52 package. ER, PR and Her2 status were extracted from the expression 693 
using probes 205225_at, 208305_at and 216836_s_t using a Gaussian mixture 694 
model. IC10 subgroups was called using iC10 package. C-indices and summary 695 
c-indices were calculated using survcomp53 package. For the combined 696 
metacohort scores, we calculated c-scores for each individual cohort and then 697 
combined them using the function combine.est from survcomp53 package. 698 
Confidence intervals and p-values for comparing c-indexes were computed with 699 
the same package. Extended Data Fig.3e shows the c-indices and confidence 700 
intervals for these comparisons. 701 
 702 
 703 
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General Statistical considerations: 704 
All tests were performed two-sided (except where indicated). Adjustment for multiple 705 
comparisons was done as described in the sections “Comparison of probabilities of 706 
relapse in ER+ high risk Integrative Subtypes” (see Supplementary Methods) and 707 
the comparison of proportions of metastases in each organ from Fig.4a and 708 
Extended Data Fig.10. All analyses were conducted in R 3.5.154 709 
 710 
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Figure Data legends 
 
Extended Data Fig.1 | Description of the cohorts used in this study. a. 
Description of the METABRIC discovery cohort, clinical characteristics and flow chart 
of sample inclusion for analysis. b. Description of the validation cohort, clinical 
characteristics and flow chart of sample inclusion for analysis. 
 779 
Extended Data Fig.2 | Effect of censoring non-malignant deaths in the 
estimation of disease-specific survival and prognostic value of clinical 
covariates at different disease states. a. Cumulative incidence computed as 1-
Kaplan-Meier estimator using only disease-specific death as endpoint and censoring 
other types of death. b. Cumulative incidence computed using a competing-risk 
model that takes into account different causes of death. The bias of the 1-Kaplan-
Meier estimator is visible. c. Distribution of age at the time of diagnosis for ER- and 
ER+ patients. The number of patients in each group is indicated in all Panels. This 
analysis was done with the FD. d. Log Hazard Ratios (HR) calculated using the 
multistate model stratified by ER status (n=3147) for different covariates, namely 
grade, lymph node (LN) status, tumor size (size), time from local relapse, time from 
surgery. Log HR are shown from different states, including post surgery (PS; HR of 
progressing to relapse or DSD), loco-regional recurrence (LR; HR of progressing to 
DR or DSD) and distant recurrence (DR; HR of cancer-specific death). 95% 
confidence intervals are shown. This analysis was done with the FD. 
 
Extended Data Fig.3 | Model calibration and validation in an external dataset. a. 780 
Internal validation of the global predictions of the models on all transitions using 781 
bootstrap (n=200). Boxplots are computed using the median of the observations, the 782 
first and third quartiles as hinges and the +/-1.58 Interquartile range divided by the 783 
square root of the sample size as notches. The optimism (difference between the 784 
training predictive ability and the test predictive ability of several discriminant 785 
measures (see Methods). b. Internal calibration of the global predictions of the 786 
models on all transitions using bootstrap (n=200). The distribution of the mean 787 
absolute error between observed and predicted is plotted. Boxplot defined as above 788 
(see Methods). c. External calibration of disease-specific death (DSD) risk and non-789 
malignant death risk using PREDICT 2.1 (n=1841). The distribution of the mean 790 
 28
absolute error between the predictions of PREDICT and our model based on ER 791 
status only is plotted. Boxplots defined as above. d. Scatterplot of the predictions of 792 
DSD risk computed by PREDICT and our model based on the IntClust subtypes only 793 
at 10 years (n=1841) (see Methods). Pearson correlation is shown. e. Concordance 794 
index (c-index) of prediction of risk of distant relapse (distant relapse free survival, 795 
DRFS), disease-specific death (disease specific survival, DSS), death (overall 796 
survival, OS) and relapse (relapse free survival, RFS) in the 178 withheld 797 
METABRIC samples and in a metacohort composed of 8 published studies amongst 798 
ER-/HER2- patients in the high-risk IntClust subtypes, where results are shown for 799 
individual cohorts and the combined metacohort (see Methods, Supplementary 800 
Information). Error bars correspond to 95% confidence intervals for the c-index. The 801 
number of patients in each group is indicated.  802 
 
Extended Data Fig.4 | Different subtypes have distinct probabilities of 
recurrence.  a. Average probability of experiencing a distant relapse (DR, defined as 
the probability of having a distant relapse at any point followed by any other 
transition) for the high risk ER+ IntClust (IC) subtypes (IC1; n=134, IC6; n=81, IC9; 
n=134, IC2; n=69) relative to IC3 (n=269), the best prognosis ER+ subgroup. This 
analysis was restricted to ER+/HER2- cases, which represent the vast majority for 
each of these subtypes. Error bars represent 95% confidence intervals for the mean. 
b. As in Panel (a), but showing the average probability of experiencing DR or cancer 
related death after a LR (IC1; n=21, IC6; n=10, IC9; n=21, IC2; n=13, IC3; n=30). c. 
Average probability of recurrence (distant relapse or cancer-specific death) after 
loco-regional relapse for all patients in each of the 11 IntClust subtypes. d. Median 
time until an additional relapse (DR or cancer specific death) after LR for all patients 
in each the 11 IntClust subtypes (n=270). This has been computed using a Kaplan-
Meier approach with competing risks of progression and non-malignant death. Error 
bars represent 95% confidence intervals for the median time. Asterisks denote 
situations where the median time cannot be computed because less than 50% of the 
patients relapsed. This analysis was done with the MD. e. Average probability of 
cancer related death after DR for all patients by subtype. f. As in Panel (d), except 
that the median time until cancer specific death after DR is shown (n=596). g. Mean 
probabilities of having relapse after surgery and after being 5 and 10 years disease-
free (see Methods and Supplementary Table 3) for the patients in each of the four 
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clinical subtypes. Error bars represent 95% confidence intervals. The number of 
patients in each group is indicated. h, i, j, k. Same as Panels (b, c, d, e) for the IHC 
subtypes (same sample sizes). l. As in Panel (g) but for the PAM50 subtypes. The 
number of patients in each group is indicated. m, n, o, p. Same as Panels (b, c, d, e) 
for the PAM50 subtypes (same sample sizes except for Panel (p); n=593). 
 
Extended Data Fig.5 | The ER-/HER2- integrative subtypes exhibit distinct risks 803 
of relapse. Probabilities of distant relapse (DR) or cancer related death (C/D) 804 
amongst ER-/Her2- patients who were disease free at 5 years post diagnosis reveals 805 
dramatic differences in the risk of relapse for TNBC IntClust (IC) subtypes IC4ER- 806 
versus the IC10 (Basal-like enriched) subtype. Here the base clinical model with IHC 807 
subtypes is compared with the base clinical model plus IntClust subtype information. 808 
Error bars represent 95% confidence intervals. The number of patients in each group 809 
is indicated. 810 
 811 
Extended Data Fig.6 | Subtype specific risks of relapse after loco-regional 
relapse. Transition probabilities from LR to other states (LR=Loco-regional relapse, 
DR=Distant relapse, D/C=Cancer/disease specific death, D/O=Death by other 
causes) for individual average patients stratified based on ER status, IHC, PAM50, 
or IntClust subtypes. 95% confidence bands were computed using bootstrap. This 
analysis was done with the FD for ER+/ER- comparisons and the MD for the 
remainder. 
 
Extended Data Fig.7 | Associations between probabilities of distant relapse 10 
years after loco-regional relapse with clinico-pathological and molecular 
features of the primary tumor. For each patient that had a loco-regional recurrence 
(LR), the 10-year probability of having distant relapse (DR) or cancer-related death 
(D/C) is plotted against different variables. A loess fit is overlaid in order to highlight 
the relationship between the probability and tumor size or time of relapse. Boxplots 
are computed using the median of the observations, the first and third quartiles as 
hinges and the +/-1.58 interquartile range divided by the square root of the sample 
size as notches. This analysis was done with the MD and the model was stratified by 
IntClust subtype (n=257). 
 812 
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Extended Data Fig.8 | Subtype specific risks of relapse after a distant relapse. 
Transition probabilities from DR to other states (LR=Loco-regional relapse, 
DR=Distant relapse, D/C=Cancer related death, D/O=Death by other causes) for 
individual average patients stratified based on ER status, IHC, PAM50 or IntClust 
subtypes. 95% confidence bands were computed using bootstrap. This analysis was 
done with the FD for ER+/ER- comparisons and the MD for the remainder. 
 813 
Extended Data Fig.9 | Distribution of the number of relapses by molecular 
subtype. a. Times of distant recurrence (DR) for ER- and ER+ patients (n=605). 
Each dot represents a distant recurrence, coded by color for different sites. b. 
Distribution of the number of distant relapses for different subtypes (n=611), based 
on ER/HER2 status (ER+/HER2+ n=36, ER+/HER2- n=263, ER-/HER2+ n=41, ER-
/HER2- n=82), PAM50 (Basal n=79, Her2 n=69, Luminal A n=101, Luminal B n=138, 
Normal n=33) and IntClust subtypes (IC1 n=40, IC2 n=25, IC3 n=32, IC4ER+ n=46, 
IC4ER- n=16, IC5 n=72, IC6 n=23, IC7 n=24, IC8 n=54, IC9 n=38, IC10 n=52). ER 
status was imputed based on expression in 6 samples. These analyses were done 
with RD cohort. 
 
 814 
Extended Data Fig.10 | Site specific patterns of relapse in the IHC, PAM50 and 
IntClust subtypes. a. Left Panel: Percentages of patients with a given site of 
metastasis in the IHC subtypes (barplots, total numbers also indicated). Upright 
triangles indicate significant positive differences in that group with respect to the 
overall mean and inverted triangles indicate significant positive differences in that 
group with respect to the overall mean using simultaneous testing of all sites (see 
Methods). Location of metastatic sites is not anatomically accurate. Right Panel: 
Cumulative incidence functions (as 1-Kaplan-Meier estimates) for each site of 
metastasis in the IHC subtypes. The same patient can have multiple sites of 
metastasis. b. Same as in Panel (a) but for the PAM50 subtypes. c. Same as in 
Panel (a) but for the IntClust subtypes. These analyses were done with RD cohort. 
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